Finance Watch: Forma Raises $100m In Quest To Become A Sickle Cell Leader
Executive Summary
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
You may also be interested in...
Finance Watch: 2019 Ended With Near-Record VC Financings, But Some Slowing Expected In 2020
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Pipeline Watch: The ASH Bumper Edition
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Axsome Soars After Depression Trial Success
Axsome is set to file for approval in the second half of 2020.
Need a specific report? 1000+ reports available
Buy Reports